---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-073998"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:07:16.624000+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Ovid reports Takeda's Ph3 soticlestat misses primary endpoints; pipeline and cash runway update

## Summary
- Takeda's Phase 3 SKYLINE in Dravet syndrome narrowly missed primary endpoint (p=0.06) but showed significant secondary endpoints (p≤0.008).
- Takeda's Phase 3 SKYWAY in Lennox-Gastaut syndrome missed primary endpoint; safety profile consistent.
- Ovid's cash runway expected into H1 2026; pipeline milestones include OV888 Phase 2 start H2 2024, OV329 data H2 2024, OV350 IND H2 2024.
- Takeda will discuss data with regulators; Ovid will update guidance on potential milestones/royalties afterward.

## SEC filing metadata
- accession: 0000950170-24-073998
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000095017024073998/0000950170-24-073998-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000095017024073998/ovid-20240617.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-073998
- JSON: https://secwatch.observer/filing/0000950170-24-073998.json
- Plain text: https://secwatch.observer/filing/0000950170-24-073998.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.